#AASLD25: Rivus’ MASH drug cuts liver fat, preserves muscle in mid-stage trial

Rivus Pharmaceuticals’ MASH candidate reduced liver fat levels by up to 31.2% at six months in a Phase 2 trial in 228 overweight and obese MASH patients. Dosed at 150 mg, 300 mg and 450 ...